Literature DB >> 12199788

Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome.

Bridget T Heelan1, Vincent Tormey, Peter Amlot, Elspeth Payne, Atul Mehta, A David B Webster.   

Abstract

Fas (CD95) plays an important role in apoptosis. Patients with defects in Fas have an autoimmune lymphoproliferative syndrome (ALPS) characterized by lymphadenopathy, autoimmune cytopenias and an increased incidence of lymphomas. There are approximately 70 known cases described worldwide. The autoimmune cytopenias are difficult to treat in this group. We describe a patient with a defect in the death domain of the FAS molecule who had autoimmune thrombocytopenia resistant to conventional therapy but which responded to a combination of rituximab and vincristine.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12199788     DOI： 10.1046/j.1365-2141.2002.03753.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  Therapeutic strategies in common variable immunodeficiency.

Authors:  W A Carrock Sewell; Matthew Buckland; Stephen R A Jolles
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  The ITP syndrome: pathogenic and clinical diversity.

Authors:  Douglas B Cines; James B Bussel; Howard A Liebman; Eline T Luning Prak
Journal:  Blood       Date:  2009-04-24       Impact factor: 22.113

Review 3.  Refractory idiopathic immune thrombocytopenic purpura in children: current and future treatment options.

Authors:  Paul Imbach
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

4.  Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).

Authors:  V Koneti Rao; Susan Price; Katie Perkins; Patricia Aldridge; Jean Tretler; Joie Davis; Janet K Dale; Fred Gill; Kip R Hartman; Linda C Stork; David J Gnarra; Lakshmanan Krishnamurti; Peter E Newburger; Jennifer Puck; Thomas Fleisher
Journal:  Pediatr Blood Cancer       Date:  2009-07       Impact factor: 3.167

Review 5.  Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).

Authors:  David T Teachey; Alix E Seif; Stephan A Grupp
Journal:  Br J Haematol       Date:  2009-11-23       Impact factor: 6.998

6.  B cells in autoimmune diabetes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2005-11-10

Review 7.  Genetic defects of apoptosis and primary immunodeficiency.

Authors:  Helen C Su; Michael J Lenardo
Journal:  Immunol Allergy Clin North Am       Date:  2008-05       Impact factor: 3.479

Review 8.  Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.

Authors:  Valerie I Brown; Alix E Seif; Gregor S D Reid; David T Teachey; Stephan A Grupp
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

9.  Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene.

Authors:  Andrew Wei; Tiffany Cowie
Journal:  Eur J Haematol       Date:  2007-08-28       Impact factor: 2.997
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.